EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY-NC-ND 4.0

Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers

Anna L Parks, Ayush Thacker, Daniel Dohan, Liliana A Ramirez Gomez, Seth A Gale, Kim G Johnson, Christine S Ritchie, Sachin J Shah, Joanna Paladino

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-07 · 11 (3)

DOI: 10.1002/trc2.70150 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 26.08.2025. Verfasst von Anna L Parks und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Hematologic Malignancies University of Utah Salt Lake City Utah USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, American Society of Hematology, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Anti‐amyloid monoclonal antibodies (mAbs) slow cognitive decline in Alzheimer's disease but may cause amyloid‐related imaging abnormalities (ARIA), which can rarely be disabling or fatal. This qualitative study investigates how clinicians communicate the benefits and risks of mAbs to patients and caregivers. METHODS Semi‐structured interviews with clinicians who prescribe mAbs at seven academic medical centers. Hybrid inductive‐deductive thematic analysis by interdisciplinary researchers. RESULTS In 27 clinician interviews (women [ n = 17], White individuals [ n = 19], neurologists [ n = 17]), three themes emerged. First, clinicians varied in techniques used and concepts emphasized, including using analogies, discussing statistics, and emphasizing versus de‐emphasizing risks. Second, patient contextual factors (e.g., comorbidities), hopes, and fears shaped communication. Third, clinician communication varied by training, personal style, and ambivalence. While clinicians honor patients’ choices to pursue treatment, many do not “recommend” it (but may recommend against it). DISCUSSION Preliminary insights about how clinicians communicate tradeoffs can guide future shared decision‐making interventions for mAbs. Highlights This qualitative study among 27 clinicians across seven academic medical centers examined how clinicians communicate with people with Alzheimer's disease about risks and benefits of anti‐amyloid therapy, which can influence treatment decisions. Clinicians varied in what techniques they employed and how they portrayed risks and benefits, and whether they incorporated patients’ values. They cited comorbidities, eligibility criteria fit, and degree of social support or family involvement in decisions as factors used in framing discussions, while fewer used patients’ goals to guide discussion. The professional training, individual practice style, and personal sense of ambivalence of clinicians shaped conversations. These findings can guide future interventions to improve communication and shared decision‐making.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseanti‐amyloid monoclonal antibodiesdementia care and practicemild cognitive impairmentqualitative methodsshared decision‐making

Autor:innen und Institutionen

  • Division of Hematology and Hematologic Malignancies University of Utah Salt Lake City Utah USA.
  • Mongan Institute Center for Aging and Serious Illness Massachusetts General Hospital Boston Massachusetts USA.
  • Institute for Health Policy Studies University of California San Francisco San Francisco California USA.
  • Memory Disorders Division Department of Neurology Massachusetts General Hospital Boston Massachusetts USA.
  • Memory Disorders Division Department of Neurology Brigham and Women's Hospital Boston Massachusetts USA.
  • Department of Psychiatry and Neurology Duke University Durham North Carolina USA.

Förderung

  • NIA NIH HHS
  • American Society of Hematology
  • National Institute on Aging

Zitieren

APA

Parks, A. L., Thacker, A., Dohan, D., Gomez, L. A. R., Gale, S. A., Johnson, K. G., Ritchie, C. S., Shah, S. J., & Paladino, J. (2025). Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(3). https://doi.org/10.1002/trc2.70150

Vancouver

Parks AL, Thacker A, Dohan D, Gomez LAR, Gale SA, Johnson KG, et al. Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(3). doi:10.1002/trc2.70150

BibTeX
@article{Parks2025,
  author = {Parks, Anna L and Thacker, Ayush and Dohan, Daniel and Gomez, Liliana A Ramirez and Gale, Seth A and Johnson, Kim G and Ritchie, Christine S and Shah, Sachin J and Paladino, Joanna},
  title = {Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2025},
  volume = {11},
  number = {3},
  doi = {10.1002/trc2.70150}
}
Kostenlos starten →